Study to Evaluate CCS1477 (inobrodib) in Haematological Malignancies
NCT04068597
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients. The study focuses on a specific combination of therapies that may improve outcomes for individuals dealing with this condition. Here are some key details about the study:
- The study is unique because it combines multiple treatment strategies, which may enhance effectiveness compared to standard therapies.
- Participants will receive a combination of medications that target different aspects of the disease, potentially leading to better management of symptoms and progression.
- The study includes a diverse group of patients, allowing researchers to assess how well the treatment works across different demographics.
- Patients will be monitored closely throughout the study to evaluate the safety and effectiveness of the treatment regimen.
- This research aims to provide insights into how combining therapies can lead to improved patient outcomes and possibly set new standards for treatment.
Third Opinion AI Generated Synopsis
Trial Summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
